Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47

Science Translational Medicine

Volumn 2, Issue 63, 2010, Pages

  Chao, Mark P ^a   Jaiswal, Siddhartha ^a,b   Weissman Tsukamoto, Rachel ^a   Alizadeh, Ash A ^a,c   Gentles, Andrew J ^c   Volkmer, Jens ^a   Weiskopf, Kipp ^a   Willingham, Stephen B ^a   Raveh, Tal ^a   Park, Christopher Y ^d   Majeti, Ravindra ^a,c   Weissman, Irving L ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c STANFORD UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CALRETICULIN; CD47 ANTIBODY; CD47 ANTIGEN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL PROTECTION; CELL SURFACE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE EVASION; MALIGNANT NEOPLASTIC DISEASE; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; BLADDER TUMOR; CELL LINE; FLOW CYTOMETRY; IN VITRO STUDY; METABOLISM; MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD47; CALRETICULIN; CELL LINE; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MICE; PHAGOCYTOSIS; URINARY BLADDER NEOPLASMS;

EID: 78650664067     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001375     Document Type: Article

References (55)

1. D. Hanahan, R. A. Weinberg, The hallmarks of cancer. Cell 100, 57-70 (2000).
2. J. Stagg, R. W. Johnstone, M. J. Smyth, From cancer immunosurveillance to cancer immunotherapy. Immunol. Rev. 220, 82-101 (2007).
3. J. B. Swann, M. J. Smyth, Immune surveillance of tumors. J. Clin. Invest. 117, 1137-1146 (2007).
4. L. Zitvogel, A. Tesniere, G. Kroemer, Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715-727 (2006).
5. S. Jaiswal, C. H. Jamieson, W. W. Pang, C. Y. Park, M. P. Chao, R. Majeti, D. Traver, N. van Rooijen, I. L. Weissman, CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271-285 (2009).
6. R. Majeti, M. P. Chao, A. A. Alizadeh, W. W. Pang, S. Jaiswal, K. D. Gibbs Jr., N. van Rooijen, I. L. Weissman, CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299 (2009).
7. S. Jaiswal, M. P. Chao, R. Majeti, I. L. Weissman, Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 31, 212-219 (2010).
8. K. S. Chan, I. Espinosa, M. Chao, D. Wong, L. Ailles, M. Diehn, H. Gill, J. Presti Jr., H. Y. Chang, M. van de Rijn, L. Shortliffe, I. L. Weissman, Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. U.S.A. 106, 14016-14021 (2009).
9. M. P. Chao, A. A. Alizadeh, C. Tang, J. H. Myklebust, B. Varghese, S. Gill, M. Jan, A. C. Cha, C. K. Chan, B. T. Tan, C. Y. Park, F. Zhao, H. E. Kohrt, R. Malumbres, J. Briones, R. D. Gascoyne, I. S. Lossos, R. Levy, I. L. Weissman, R. Majeti, Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699-713 (2010).
10. R. K. Tsai, P. L. Rodriguez, D. E. Discher, Self inhibition of phagocytosis: The affinity of 'marker of self' CD47 for SIRPa dictates potency of inhibition but only at low expression levels. Blood Cells Mol. Dis. 45, 67-74 (2010).
11. A. N. Barclay, M. H. Brown, The SIRP family of receptors and immune regulation. Nat. Rev. Immunol. 6, 457-464 (2006).
12. P. Jiang, C. F. Lagenaur, V. Narayanan, Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J. Biol. Chem. 274, 559-562 (1999).
13. M. I. Reinhold, F. P. Lindberg, D. Plas, S. Reynolds, M. G. Peters, E. J. Brown, In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J. Cell Sci. 108, 3419-3425 (1995).
14. S. J. Gardai, K. A. McPhillips, S. C. Frasch, W. J. Janssen, A. Starefeldt, J. E. Murphy-Ullrich, D. L. Bratton, P. A. Oldenborg, M. Michalak, P. M. Henson, Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123, 321-334 (2005).
15. A. W. Orr, C. E. Pedraza, M. A. Pallero, C. A. Elzie, S. Goicoechea, D. K. Strickland, J. E. Murphy- Ullrich, Lowdensity lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly. J. Cell Biol. 161, 1179-1189 (2003).
16. T. Panaretakis, N. Joza, N. Modjtahedi, A. Tesniere, I. Vitale, M. Durchschlag, G. M. Fimia, O. Kepp, M. Piacentini, K. U. Froehlich, P. van Endert, L. Zitvogel, F. Madeo, G. Kroemer, The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 15, 1499-1509 (2008).
17. M. Obeid, ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin. J. Immunol. 181, 2533-2543 (2008).
18. T. Reya, S. J. Morrison, M. F. Clarke, I. L. Weissman, Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
19. T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M. A. Caligiuri, J. E. Dick, A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994).
20. A. Blair, D. E. Hogge, L. E. Ailles, P. M. Lansdorp, H. J. Sutherland, Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89, 3104-3112 (1997).
21. C. H. Jamieson, L. E. Ailles, S. J. Dylla, M. Muijtjens, C. Jones, J. L. Zehnder, J. Gotlib, K. Li, M. G. Manz, A. Keating, C. L. Sawyers, I. L. Weissman, Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657-667 (2004).
22. S. K. Singh, I. D. Clarke, M. Terasaki, V. E. Bonn, C. Hawkins, J. Squire, P. B. Dirks, Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828 (2003).
23. S. K. Singh, C. Hawkins, I. D. Clarke, J. A. Squire, J. Bayani, T. Hide, R. M. Henkelman, M. D. Cusimano, P. B. Dirks, Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
24. J. B. Maxhimer, D. R. Soto-Pantoja, L. A. Ridnour, H. B. Shih, W. G. Degraff, M. Tsokos, D. A. Wink, J. S. Isenberg, D. D. Roberts, Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci. Transl. Med. 1, 3ra7 (2009).
25. M. Obeid, T. Panaretakis, N. Joza, R. Tufi, A. Tesniere, P. van Endert, L. Zitvogel, G. Kroemer, Calreticulin exposure is required for the immunogenicity of g-irradiation and UVC lightinduced apoptosis. Cell Death Differ. 14, 1848-1850 (2007).
26. F. A. Arosa, O. de Jesus, G. Porto, A. M. Carmo, M. de Sousa, Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibility complex class I molecules. J. Biol. Chem. 274, 16917-16922 (1999).
27. I. Ghiran, L. B. Klickstein, A. Nicholson-Weller, Calreticulin is at the surface of circulating neutrophils and uses CD59 as an adaptor molecule. J. Biol. Chem. 278, 21024-21031 (2003).
28. Y. J. Park, G. Liu, E. F. Lorne, X. Zhao, J. Wang, Y. Tsuruta, J. Zmijewski, E. Abraham, PAI-1 inhibits neutrophil efferocytosis. Proc. Natl. Acad. Sci. U.S.A. 105, 11784-11789 (2008).
29. D. W. Lawrence, S. B. King, W. A. Frazier, J. M. Koenig, Decreased CD47 expression during spontaneous apoptosis targets neutrophils for phagocytosis by monocyte-derived macrophages. Early Hum. Dev. 85, 659-663 (2009).
30. M. Obeid, A. Tesniere, F. Ghiringhelli, G. M. Fimia, L. Apetoh, J. L. Perfettini, M. Castedo, G. Mignot, T. Panaretakis, N. Casares, D. Métivier, N. Larochette, P. van Endert, F. Ciccosanti, M. Piacentini, L. Zitvogel, G. Kroemer, Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007). (Pubitemid 46067386)
31. J. Connor, C. Bucana, I. J. Fidler, A. J. Schroit, Differentiation- dependent expression of phosphatidylserine in mammalian plasma membranes: Quantitative assessment of outer-leaflet lipid by prothrombinase complex formation. Proc. Natl. Acad. Sci. U.S.A. 86, 3184-3188 (1989).
32. T. Utsugi, A. J. Schroit, J. Connor, C. D. Bucana, I. J. Fidler, Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51, 3062-3066 (1991).
33. L. V. Rao, J. F. Tait, A. D. Hoang, Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity. Thromb. Res. 67, 517-531 (1992).
34. H. Woehlecke, A. Pohl, N. Alder-Baerens, H. Lage, A. Herrmann, Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2). Biochem. J. 376, 489-495 (2003).
35. R. F. Zwaal, P. Comfurius, E. M. Bevers, Surface exposure of phosphatidylserine in pathological cells. Cell. Mol. Life Sci. 62, 971-988 (2005).
36. L. H. Lim, S. Pervaiz, Annexin 1: The new face of an old molecule. FASEB J. 21, 968-975 (2007).
37. J. Savill, I. Dransfield, C. Gregory, C. Haslett, A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2, 965-975 (2002).
38. D. K. Strickland, M. Z. Kounnas, W. S. Argraves, LDL receptor-related protein: A multiligand receptor for lipoprotein and proteinase catabolism. FASEB J. 9, 890-898 (1995).
39. M. Liu, H. Imam, K. Oberg, Y. Zhou, Gene transfer of vasostatin, a calreticulin fragment, into neuroendocrine tumor cells results in enhanced malignant behavior. Neuroendocrinology 82, 1-10 (2005).
40. C. N. Chen, C. C. Chang, T. E. Su, W. M. Hsu, Y. M. Jeng, M. C. Ho, F. J. Hsieh, P. H. Lee, M. L. Kuo, H. Lee, K. J. Chang, Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann. Surg. Oncol. 16, 524-533 (2009).
41. S. E. Pike, L. Yao, J. Setsuda, K. D. Jones, B. Cherney, E. Appella, K. Sakaguchi, H. Nakhasi, C. D. Atreya, J. Teruya-Feldstein, P. Wirth, G. Gupta, G. Tosato, Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94, 2461-2468 (1999).
42. S. E. Pike, L. Yao, K. D. Jones, B. Cherney, E. Appella, K. Sakaguchi, H. Nakhasi, J. Teruya- Feldstein, P. Wirth, G. Gupta, G. Tosato, Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J. Exp. Med. 188, 2349-2356 (1998).
43. W. M. Hsu, F. J. Hsieh, Y. M. Jeng, M. L. Kuo, C. N. Chen, D. M. Lai, L. J. Hsieh, B. T. Wang, P. N. Tsao, H. Lee, M. T. Lin, H. S. Lai, W. J. Chen, Calreticulin expression in neuroblastoma-a novel independent prognostic factor. Ann. Oncol. 16, 314-321 (2005).
44. M. G. Coppolino, M. J.Woodside, N. Demaurex, S. Grinstein, R. St-Arnaud, S. Dedhar, Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature 386, 843-847 (1997).
45. C. Howe, M. Garstka, M. Al-Balushi, E. Ghanem, A. N. Antoniou, S. Fritzsche, G. Jankevicius, N. Kontouli, C. Schneeweiss, A. Williams, T. Elliott, S. Springer, Calreticulin-dependent recycling in the early secretory pathway mediates optimal peptide loading of MHC class I molecules. EMBO J. 28, 3730-3744 (2009).
46. G. Bu, The roles of receptor-associated protein (RAP) as a molecular chaperone for members of the LDL receptor family. Int. Rev. Cytol. 209, 79-116 (2001).
47. L. M. Obermoeller-McCormick, Y. Li, H. Osaka, D. J. FitzGerald, A. L. Schwartz, G. Bu, Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptorrelated protein. J. Cell Sci. 114, 899-908 (2001).
48. A. W. Orr, C. A. Elzie, D. F. Kucik, J. E. Murphy-Ullrich, Thrombospondin signaling through the calreticulin/LDL receptor-related protein co-complex stimulates random and directed cell migration. J. Cell Sci. 116, 2917-2927 (2003).
49. M. Dai, P. Wang, A. D. Boyd, G. Kostov, B. Athey, E. G. Jones, W. E. Bunney, R. M. Myers, T. P. Speed, H. Akil, S. J. Watson, F. Meng, Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33, e175 (2005).
50. A. Oberthuer, D. Juraeva, L. Li, Y. Kahlert, F. Westermann, R. Eils, F. Berthold, L. Shi, R. D. Wolfinger, M. Fischer, B. Brors, Comparison of performance of one-color and twocolor gene-expression analyses in predicting clinical endpoints of neuroblastoma patients. Pharmacogenomics J. 10, 258-266 (2010).
51. K. De Preter, J. Vermeulen, B. Brors, O. Delattre, A. Eggert, M. Fischer, I. Janoueix-Lerosey, C. Lavarino, J. M. Maris, J. Mora, A. Nakagawara, A. Oberthuer, M. Ohira, G. Schleiermacher, A. Schramm, J. H. Schulte, Q. Wang, F. Westermann, F. Speleman, J. Vandesompele, Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin. Cancer Res. 16, 1532-1541 (2010).
52. W. J. Kim, E. J. Kim, S. K. Kim, Y. J. Kim, Y. S. Ha, P. Jeong, M. J. Kim, S. J. Yun, K. M. Lee, S. K. Moon, S. C. Lee, E. J. Cha, S. C. Bae, Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol. Cancer 9, 3 (2010).
53. A. B. Als, L. Dyrskjøt, H. von der Maase, K. Koed, F. Mansilla, H. E. Toldbod, J. L. Jensen, B. P. Ulhøi, L. Sengeløv, K. M. Jensen, T. F. Orntoft, Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin. Cancer Res. 13, 4407-4414 (2007).
54. S. Blenk, J. C. Engelmann, S. Pinkert, M. Weniger, J. Schultz, A. Rosenwald, H. K. Müller- Hermelink, T. Müller, T. Dandekar, Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis. BMC Cancer 8, 106 (2008).
55. A. Rosenwald, G. Wright, A. Wiestner, W. C. Chan, J. M. Connors, E. Campo, R. D. Gascoyne, T. M. Grogan, H. K. Muller-Hermelink, E. B. Smeland, M. Chiorazzi, J. M. Giltnane, E. M. Hurt, H. Zhao, L. Averett, S. Henrickson, L. Yang, J. Powell, W. H. Wilson, E. S. Jaffe, R. Simon, R. D. Klausner, E. Montserrat, F. Bosch, T. C. Greiner, D. D. Weisenburger, W. G. Sanger, B. J. Dave, J. C. Lynch, J. Vose, J. O. Armitage, R. I. Fisher, T. P. Miller, M. LeBlanc, G. Ott, S. Kvaloy, H. Holte, J. Delabie, L.M. Staudt, The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3, 185-197 (2003).